We are live on ! Find out more

Becton Dickinson

BDX

Market cap $49.8B

182.75 USD

+2.59

1.44%

At close Updated Oct 8, 4:00 PM EDT

Pre-market

After hours

182.89

+0.14

0.08%

1 day

1.44%

5 days

2.98%

1 month

2.04%

3 months

21.38%

6 months

16.33%

Year to date

-6.25%

1 year

-5.76%

5 years

-21.49%

10 years

4.54%

About: Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.

Employees: 72,000

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.9%

Neutral 55.1%

Negative 2%

BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026

FRANKLIN LAKES, N.J., Oct. 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.

BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026

BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide

Physicians, policymakers, and global health experts urge broader access to monitoring technologies that can help identify life-threatening complications earlier, helping more mothers survive childbirth and giving babies a healthier start in life. FRANKLIN LAKES, N.J.

BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide

Zacks Investment Research

BDX Expands U.S. Manufacturing With $19B Healthcare Investment

BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.

BDX Expands U.S. Manufacturing With $19B Healthcare Investment

BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results

Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease. FRANKLIN LAKES, N.J.

BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results

Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing

Becton, Dickinson and Company (NYSE:BDX), a global medical technology firm and the largest domestic producer of critical medical consumables, on Tuesday announced a monumental partnership with the U.S. government.

Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing

BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan

Generations of Connecticut employees have helped ensure the reliable supply of the BD® Syringe, an essential medical device clinicians rely on every day in patient care around the world CANAAN, Conn., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked 65 years of manufacturing in Canaan, Conn.

BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan

BD Appoints Ferass Abuzaina as Worldwide President of Surgery

FRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Ferass Abuzaina has been named worldwide president of the Surgery business unit at BD, effective immediately.

BD Appoints Ferass Abuzaina as Worldwide President of Surgery

Becton Dickinson to invest $19 billion in US

Becton Dickinson plans to invest $19 billion in the US ‌over several years, including $3 billion to expand domestic manufacturing, as part of an agreement with the government ⁠to strengthen the supply of essential medical products.

Becton Dickinson to invest $19 billion in US

BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience

Agreement supports significant investments in U.S. manufacturing, strengthens healthcare resilience and increases domestic production of essential medical consumables used in approximately 90% of U.S. hospital visits   FRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), one of the world's leading medical technology companies and the nation's largest manufacturer of essential medical consumables, today announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by clinicians and patients every day.

BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience

Trump says Becton Dickinson to invest $3 billion to expand US medical product manufacturing

American medical technology company Becton ‌Dickinson has agreed to invest $3 billion to bring manufacturing of essential medical products ⁠to the United States, President Donald Trump said on Monday in a post on the Truth Social website.

Trump says Becton Dickinson to invest $3 billion to expand US medical product manufacturing

See News Rankings

Price charts implemented using Lightweight Charts™